Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Exegenesis Bio
Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without External Assistance
April 25, 2024
From
Exegenesis Bio
Via
Business Wire
Exegenesis Bio To Present Five Posters at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, Los Angeles, CA, May 16-20, 2023
April 05, 2023
From
Exegenesis Bio
Via
Business Wire
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
January 18, 2023
From
Exegenesis Bio
Via
Business Wire
Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer
September 16, 2021
From
Exegenesis Bio
Via
Business Wire
Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans
September 08, 2021
From
Exegenesis Bio
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.